There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Blueprint Medicines (BPMC), Henry Schein (HSIC) and Immunovant (IMVT) with bullish sentiments.
Blueprint Medicines (BPMC)
In a report released yesterday, Michael Ulz from Robert W. Baird reiterated a Buy rating on Blueprint Medicines, with a price target of $120.00. The company’s shares closed last Thursday at $97.58.
According to TipRanks.com, Ulz is a 4-star analyst with an average return of 11.2% and a 58.3% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
Blueprint Medicines has an analyst consensus of Moderate Buy, with a price target consensus of $118.09, a 18.8% upside from current levels. In a report released yesterday, Raymond James also maintained a Buy rating on the stock with a $122.00 price target.
See today’s analyst top recommended stocks >>
Henry Schein (HSIC)
Robert W. Baird analyst Jeff Johnson reiterated a Buy rating on Henry Schein today and set a price target of $79.00. The company’s shares closed last Thursday at $64.07.
According to TipRanks.com, Johnson is a 5-star analyst with an average return of 31.2% and a 71.0% success rate. Johnson covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA, Align Tech, and Dexcom.
Currently, the analyst consensus on Henry Schein is a Strong Buy with an average price target of $81.20, representing a 26.5% upside. In a report issued on February 8, Piper Sandler also initiated coverage with a Buy rating on the stock with a $83.00 price target.
Immunovant (IMVT)
Robert W. Baird analyst Brian Skorney maintained a Buy rating on Immunovant on February 16 and set a price target of $32.00. The company’s shares closed last Thursday at $19.34.
According to TipRanks.com, Skorney is a 4-star analyst with an average return of 8.2% and a 54.5% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Myovant Sciences, and Gilead Sciences.
Currently, the analyst consensus on Immunovant is a Strong Buy with an average price target of $40.13, which is an 114.8% upside from current levels. In a report issued on February 2, Truist Financial also maintained a Buy rating on the stock with a $48.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
